Publications

1: Dobosz P, Stempor PA, Roszik J, Herman A, Layani A, Berger R, Avni D, Sidi Y,

Leibowitz-Amit R. Checkpoint Genes at the Cancer Side of the Immunological

Synapse in Bladder Cancer. Transl Oncol. 2019 Dec 20;13(2):193-200. doi:

10.1016/j.tranon.2019.10.018. [Epub ahead of print] PubMed PMID: 31869744.

2: Percik R, Shlomai G, Tirosh A, Tirosh A, Leibowitz-Amit R, Eshet Y, Greenberg

G, Merlinsky A, Barhod E, Steinberg-Silman Y, Sella T. Isolated autoimmune

adrenocorticotropic hormone deficiency: From a rare disease to the dominant cause

of adrenal insufficiency related to check point inhibitors. Autoimmun Rev. 2019

Dec 12:102454. doi: 10.1016/j.autrev.2019.102454. [Epub ahead of print] Review.

PubMed PMID: 31838158.

3: Petrylak DP, et al; RANGE study investigators. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after

platinum-based therapy (RANGE): overall survival and updated results of a

randomised, double-blind, phase 3 trial. Lancet Oncol. 2019 Nov 18. pii:

S1470-2045(19)30668-0. doi: 10.1016/S1470-2045(19)30668-0. [Epub ahead of print]

PubMed PMID: 31753727.

4: Bar J, Markel G, Gottfried T, Percik R, Leibowitz-Amit R, Berger R, Golan T,

Daher S, Taliansky A, Dudnik E, Shulman K, Urban D, Onn A. Acute vascular events

as a possibly related adverse event of immunotherapy: a single-institute

retrospective study. Eur J Cancer. 2019 Oct;120:122-131. doi:

10.1016/j.ejca.2019.06.021. Epub 2019 Sep 10. PubMed PMID: 31518968.

5: Roszik J, Markovits E, Dobosz P, Layani A, Slabodnik-Kaner K, Baruch EN,

Ben-Betzalel G, Grimm E, Berger R, Sidi Y, Schachter J, Shapira-Frommer R, Avni

D, Markel G, Leibowitz-Amit R. TNFSF4 (OX40L) expression and survival in locally

advanced and metastatic melanoma. Cancer Immunol Immunother. 2019

Sep;68(9):1493-1500. doi: 10.1007/s00262-019-02382-0. Epub 2019 Sep 9. PubMed

PMID: 31501955.

6: Motzer RJ, et al; CheckMate 214 investigators. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019 Oct;20(10):1370-1385.

doi: 10.1016/S1470-2045(19)30413-9. Epub 2019 Aug 16. Erratum in: Lancet Oncol.

2019 Aug 21;:. PubMed PMID: 31427204.

7: O'Kane GM, Ezzat S, Joshua AM, Bourdeau I, Leibowitz-Amit R, Olney HJ,

Krzyzanowska M, Reuther D, Chin S, Wang L, Brooks K, Hansen AR, Asa SL, Knox JJ.

A phase 2 trial of sunitinib in patients with progressive paraganglioma or

pheochromocytoma: the SNIPP trial. Br J Cancer. 2019 Jun;120(12):1113-1119. doi:

10.1038/s41416-019-0474-x. Epub 2019 May 20. PubMed PMID: 31105270; PubMed

Central PMCID: PMC6738062.

8: Leibowitz-Amit R. Reply to Joe O'Sullivan, Daniel Heinrich, Nicholas D. James,

et al's Letter to the Editor re: The Case Against the European Medicines Agency's

Change to the Label for Radium-223 for the Treatment of Metastatic

Castration-resistant Prostate Cancer. Eur Urol 2019;75:e53. Eur Urol. 2019

Jul;76(1):e19. doi: 10.1016/j.eururo.2019.03.013. Epub 2019 Mar 28. PubMed PMID:

30928161.

9: Gianni M, Qin Y, Wenes G, Bandstra B, Conley AP, Subbiah V, Leibowitz-Amit R,

Ekmekcioglu S, Grimm EA, Roszik J. High-Throughput Architecture for Discovering

Combination Cancer Therapeutics. JCO Clin Cancer Inform. 2018 Dec;2:1-12. doi:

10.1200/CCI.17.00054. PubMed PMID: 30652536; PubMed Central PMCID: PMC6873994.

10: Hammer L, Laufer M, Dotan Z, Leibowitz-Amit R, Berger R, Felder S, Weiss I,

Lawrence YR, Symon Z. Accelerated Hypofractionated Radiation Therapy for Elderly

Frail Bladder Cancer Patients Unfit for Surgery or Chemotherapy. Am J Clin Oncol.

2019 Feb;42(2):179-183. doi: 10.1097/COC.0000000000000491. PubMed PMID: 30451730.

11: Kaiser J, Li H, North SA, Leibowitz-Amit R, Seah JA, Morshed N, Chau C,

Lee-Ying R, Heng DYC, Sridhar S, Crabb SJ, Alimohamed NS. The Prognostic Role of

the Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy in

Patients with Muscle-Invasive Bladder Cancer: A Retrospective,

Multi-Institutional Study. Bladder Cancer. 2018 Apr 26;4(2):185-194. doi:

10.3233/BLC-170133. PubMed PMID: 29732389; PubMed Central PMCID: PMC5929304.

12: Motzer RJ, et al; CheckMate 214 Investigators. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi:

10.1056/NEJMoa1712126. Epub 2018 Mar 21. PubMed PMID: 29562145; PubMed Central

PMCID: PMC5972549.

13: Abu-Ghanem Y, Ramon J, Berger R, Kaver I, Fridman E, Leibowitz-Amit R, Dotan

ZA. Positive surgical margin following radical nephrectomy is an independent

predictor of local recurrence and disease-specific survival. World J Surg Oncol.

2017 Nov 2;15(1):193. doi: 10.1186/s12957-017-1257-6. PubMed PMID: 29096642;

PubMed Central PMCID: PMC5668980.

14: Mizrahi A, Barzilai A, Gur-Wahnon D, Ben-Dov IZ, Glassberg S, Meningher T,

Elharar E, Masalha M, Jacob-Hirsch J, Tabibian-Keissar H, Barshack I, Roszik J,

Leibowitz-Amit R, Sidi Y, Avni D. Alterations of microRNAs throughout the

malignant evolution of cutaneous squamous cell carcinoma: the role of miR-497 in

epithelial to mesenchymal transition of keratinocytes. Oncogene. 2018 Jan

11;37(2):218-230. doi: 10.1038/onc.2017.315. Epub 2017 Sep 18. PubMed PMID:

28925390.

15: Petrylak DP, et al; RANGE study investigators. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after

platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.

Lancet. 2017 Nov 18;390(10109):2266-2277. doi: 10.1016/S0140-6736(17)32365-6.

Epub 2017 Sep 12. PubMed PMID: 28916371.

16: Saad A, Goldstein J, Lawrence YR, Spieler B, Leibowitz-Amit R, Berger R,

Davidson T, Urban D, Tsang L, Alezra D, Weiss I, Symon Z. Classifying high-risk

versus very high-risk prostate cancer: is it relevant to outcomes of conformal

radiotherapy and androgen deprivation? Radiat Oncol. 2017 Jan 6;12(1):5. doi:

10.1186/s13014-016-0743-2. PubMed PMID: 28061904; PubMed Central PMCID:

PMC5216523.

17: Leibowitz-Amit R, Israel A, Gal M, Atenafu EA, Symon Z, Portnoy O, Laufer M,

Dotan Z, Ramon J, Avni D, Fridman E, Berger R. Association between the Absolute

Baseline Lymphocyte Count and Response to Neoadjuvant Platinum-based Chemotherapy

in Muscle-invasive Bladder Cancer. Clin Oncol (R Coll Radiol). 2016

Dec;28(12):790-796. doi: 10.1016/j.clon.2016.07.007. Epub 2016 Aug 5. PubMed

PMID: 27498850.

18: Bonen H, Kol N, Shomron N, Leibowitz-Amit R, Quagliata L, Lorber T, Sidi Y,

Avni D. Promoter-Associated RNAs Regulate HSPC152 Gene Expression in Malignant

Melanoma. Noncoding RNA. 2016 Jun 30;2(3). pii: E7. doi: 10.3390/ncrna2030007.

PubMed PMID: 29657265; PubMed Central PMCID: PMC5831909.

19: Leibowitz-Amit R, Pintilie M, Khoja L, Azad AA, Berger R, Laird AD, Aftab DT,

Chi KN, Joshua AM. Changes in plasma biomarkers following treatment with

cabozantinib in metastatic castration-resistant prostate cancer: a post hoc

analysis of an extension cohort of a phase II trial. J Transl Med. 2016 Jan

13;14:12. doi: 10.1186/s12967-015-0747-y. PubMed PMID: 26762579; PubMed Central

PMCID: PMC4712499.

20: Zehavi L, Schayek H, Jacob-Hirsch J, Sidi Y, Leibowitz-Amit R*, Avni D.

MiR-377 targets E2F3 and alters the NF-kB signaling pathway through MAP3K7 in

malignant melanoma. Mol Cancer. 2015 Mar 26;14:68. doi:

10.1186/s12943-015-0338-9. PubMed PMID: 25889255; PubMed Central PMCID:

PMC4392476.* Equal corresponding author

21: Seah JA, Leibowitz-Amit R*, Atenafu EG, Alimohamed N, Knox JJ, Joshua AM,

Sridhar SS. Neutrophil-Lymphocyte Ratio and Pathological Response to Neoadjuvant

Chemotherapy in Patients With Muscle-Invasive Bladder Cancer. Clin Genitourin

Cancer. 2015 Aug;13(4):e229-e233. doi: 10.1016/j.clgc.2015.02.001. Epub 2015 Feb

7. PubMed PMID: 25777682. * equal contribution

22: Keizman D, Rouvinov K, Sella A, Gottfried M, Maimon N, Kim JJ, Eisenberger

MA, Sinibaldi V, Peer A, Carducci MA, Mermershtain W, Leibowitz-Amit R, Weitzen

R, Berger R. Is there a "Trial Effect" on Outcome of Patients with Metastatic

Renal Cell Carcinoma Treated with Sunitinib? Cancer Res Treat. 2016

Jan;48(1):281-7. doi: 10.4143/crt.2014.289. Epub 2015 Mar 5. PubMed PMID:

25761478; PubMed Central PMCID: PMC4720089.

23: Leibowitz-Amit R, Khoja L, Tannock IF, Joshua AM. Choosing a better end point

for trials of bone-protective agents. Ann Oncol. 2015 May;26(5):1032-3. doi:

10.1093/annonc/mdv039. Epub 2015 Jan 28. PubMed PMID: 25632065.

24: Leibowitz-Amit R, Templeton AJ, Alibhai SM, Knox JJ, Sridhar SS, Tannock IF,

Joshua AM. Efficacy and toxicity of abiraterone and docetaxel in octogenarians

with metastatic castration-resistant prostate cancer. J Geriatr Oncol. 2015

Jan;6(1):23-8. doi: 10.1016/j.jgo.2014.09.183. Epub 2014 Oct 7. PubMed PMID:

25301537.

25: Lerman G, Sharon M, Leibowitz-Amit R, Sidi Y, Avni D. The crosstalk between

IL-22 signaling and miR-197 in human keratinocytes. PLoS One. 2014 Sep

10;9(9):e107467. doi: 10.1371/journal.pone.0107467. eCollection 2014. PubMed

PMID: 25208211; PubMed Central PMCID: PMC4160297.

26: Azad AA, Leibowitz-Amit R*, Eigl BJ, Lester R, Wells JC, Murray RN,

Kollmannsberger C, Heng DY, Joshua AM, Chi KN. A retrospective, Canadian

multi-center study examining the impact of prior response to abiraterone acetate

on efficacy of docetaxel in metastatic castration-resistant prostate cancer.

Prostate. 2014 Nov;74(15):1544-50. doi: 10.1002/pros.22872. Epub 2014 Aug 29.

PubMed PMID: 25175831. * equal contribution

27: Leibowitz-Amit R, Alimohamed N, Vera-Badillo FE, Seah JA, Templeton AJ, Knox

JJ, Tannock IF, Sridhar SS, Joshua AM. Retreatment of men with metastatic

castrate-resistant prostate cancer with abiraterone. Prostate. 2014

Oct;74(14):1462-4. doi: 10.1002/pros.22861. Epub 2014 Aug 11. PubMed PMID:

25111736.

28: Leibowitz-Amit R, Seah JA, Atenafu EG, Templeton AJ, Vera-Badillo FE,

Alimohamed N, Knox JJ, Tannock IF, Sridhar SS, Joshua AM. Abiraterone acetate in

metastatic castration-resistant prostate cancer: a retrospective review of the

Princess Margaret experience of (I) low dose abiraterone and (II) prior

ketoconazole. Eur J Cancer. 2014 Sep;50(14):2399-407. doi:

10.1016/j.ejca.2014.06.004. Epub 2014 Jul 16. PubMed PMID: 25042152.

29: Templeton AJ, Pezaro C, Omlin A, McNamara MG, Leibowitz-Amit R, Vera-Badillo

FE, Attard G, de Bono JS, Tannock IF, Amir E. Simple prognostic score for

metastatic castration-resistant prostate cancer with incorporation of

neutrophil-to-lymphocyte ratio. Cancer. 2014 Nov 1;120(21):3346-52. doi:

10.1002/cncr.28890. Epub 2014 Jul 3. PubMed PMID: 24995769.

30: Leibowitz-Amit R, Mete O, Asa SL, Ezzat S, Joshua AM. Malignant

pheochromocytoma secreting vasoactive intestinal peptide and response to

sunitinib: a case report and literature review. Endocr Pract. 2014

Aug;20(8):e145-50. doi: 10.4158/EP14093.CR. Erratum in: Endocr Pract. 2015

Jan;21(1):94. Lebowitz-Amit, Raya [corrected to Leibowitz-Amit, Raya]. PubMed

PMID: 24936559.

31: Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A,

Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E. Prognostic

role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and

meta-analysis. J Natl Cancer Inst. 2014 May 29;106(6):dju124. doi:

10.1093/jnci/dju124. Print 2014 Jun. Review. PubMed PMID: 24875653.

32: Azad AA, Eigl BJ, Leibowitz-Amit R, Lester R, Kollmannsberger C, Murray N,

Clayton R, Heng DY, Joshua AM, Chi KN. Outcomes with abiraterone acetate in

metastatic castration-resistant prostate cancer patients who have poor

performance status. Eur Urol. 2015 Mar;67(3):441-7. doi:

10.1016/j.eururo.2014.01.030. Epub 2014 Jan 31. PubMed PMID: 24508071.

33: Leibowitz-Amit R, Templeton AJ, Omlin A, Pezaro C, Atenafu EG, Keizman D,

Vera-Badillo F, Seah JA, Attard G, Knox JJ, Sridhar SS, Tannock IF, de Bono JS,

Joshua AM. Clinical variables associated with PSA response to abiraterone acetate

in patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2014

Mar;25(3):657-62. doi: 10.1093/annonc/mdt581. Epub 2014 Jan 23. PubMed PMID:

24458472; PubMed Central PMCID: PMC4433513.

34: Peer A, Gottfried M, Sinibaldi V, Carducci MA, Eisenberger MA, Sella A,

Leibowitz-Amit R, Berger R, Keizman D. Comparison of abiraterone acetate versus

ketoconazole in patients with metastatic castration resistant prostate cancer

refractory to docetaxel. Prostate. 2014 Apr;74(4):433-40. doi:

10.1002/pros.22765. Epub 2013 Dec 11. PubMed PMID: 24338986; PubMed Central

PMCID: PMC4696030.

35: Templeton AJ, Vera-Badillo FE, Wang L, Attalla M, De Gouveia P,

Leibowitz-Amit R, Knox JJ, Moore M, Sridhar SS, Joshua AM, Pond GR, Amir E,

Tannock IF. Translating clinical trials to clinical practice: outcomes of men

with metastatic castration resistant prostate cancer treated with docetaxel and

prednisone in and out of clinical trials. Ann Oncol. 2013 Dec;24(12):2972-7. doi:

10.1093/annonc/mdt397. Epub 2013 Oct 14. PubMed PMID: 24126362.

36: Leibowitz-Amit R, Joshua AM. The changing landscape in metastatic

castration-resistant prostate cancer. Curr Opin Support Palliat Care. 2013

Sep;7(3):243-8. doi: 10.1097/SPC.0b013e328362ffef. Review. PubMed PMID: 23817317.

37: Leibowitz-Amit R, Joshua AM. Targeting the androgen receptor in the

management of castration-resistant prostate cancer: rationale, progress, and

future directions. Curr Oncol. 2012 Dec;19(Suppl 3):S22-31. doi:

10.3747/co.19.1281. PubMed PMID: 23355790; PubMed Central PMCID: PMC3553559.

38: Leibowitz-Amit R, Sidi Y, Avni D. Aberrations in the micro-RNA biogenesis

machinery and the emerging roles of micro-RNAs in the pathogenesis of cutaneous

malignant melanoma. Pigment Cell Melanoma Res. 2012 Nov;25(6):740-57. doi:

10.1111/pcmr.12018. Review. PubMed PMID: 22958787.

39: Zehavi L, Avraham R, Barzilai A, Bar-Ilan D, Navon R, Sidi Y, Avni D,

Leibowitz-Amit R. Silencing of a large microRNA cluster on human chromosome 14q32

in melanoma: biological effects of mir-376a and mir-376c on insulin growth factor

1 receptor. Mol Cancer. 2012 Jul 2;11:44. PubMed PMID: 22747855; PubMed Central

PMCID: PMC3444916.

40: Leibowitz-Amit R, Tsarfaty G, Abargil Y, Yerushalmi GM, Horev J, Tsarfaty I.

Mimp, a mitochondrial carrier homologue, inhibits Met-HGF/SF-induced scattering

and tumorigenicity by altering Met-HGF/SF signaling pathways. Cancer Res. 2006

Sep 1;66(17):8687-97. PubMed PMID: 16951184.

41: Yerushalmi GM, Leibowitz-Amit R*, Shaharabany M, Tsarfaty I. Met-HGF/SF signal

transduction induces mimp, a novel mitochondrial carrier homologue, which leads

to mitochondrial depolarization. Neoplasia. 2002 Nov-Dec;4(6):510-22. PubMed

PMID: 12407445; PubMed Central PMCID: PMC1503665.* equal contribution

42: Hauben E, Butovsky O, Nevo U, Yoles E, Moalem G, Agranov E, Mor F,

Leibowitz-Amit R, Pevsner E, Akselrod S, Neeman M, Cohen IR, Schwartz M. Passive

or active immunization with myelin basic protein promotes recovery from spinal

cord contusion. J Neurosci. 2000 Sep 1;20(17):6421-30. Erratum in: J Neurosci.

2016 Feb 10;36(6):2075. PubMed PMID: 10964948; PubMed Central PMCID: PMC6772980.

43: Moalem G, Yoles E, Leibowitz-Amit R, Muller-Gilor S, Mor F, Cohen IR,

Schwartz M. Autoimmune T cells retard the loss of function in injured rat optic

nerves. J Neuroimmunol. 2000 Jul 1;106(1-2):189-97. PubMed PMID: 10814797.

44: Schwartz M, Moalem G, Leibowitz-Amit R, Cohen IR. Innate and adaptive immune

responses can be beneficial for CNS repair. Trends Neurosci. 1999

Jul;22(7):295-9. Review. PubMed PMID: 10370250.

45: Moalem G, Leibowitz-Amit R*, Yoles E, Mor F, Cohen IR, Schwartz M. Autoimmune

T cells protect neurons from secondary degeneration after central nervous system

axotomy. Nat Med. 1999 Jan;5(1):49-55. PubMed PMID: 9883839. * equal contribution.